ReviewGene therapy2007
Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.
Review in Gene therapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed.
- Chemistry-mediated synthetic virus-cell interaction as a generic approach to enhance gene delivery to mammalian cells.Molecular therapy. Advances · 2026Article
- Molecular Mechanism of VSV-Vectored ASFV Vaccine Activating Immune Response in DCs.Veterinary sciences · 2025Article
- Design, Preclinical Evaluation, and Clinical Translation ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Scrutiny of chimeric antigen receptor activation by the extracellular domain: experience with single domain antibodies targeting multiple myeloma cells highlights the need for case-by-case optimization.Frontiers in immunology · 2024Article
- Nanobodies in cancer.Seminars in immunology · 2021Review
- Integrase-Defective Lentiviral Vectors for Delivery of Monoclonal Antibodies against Influenza.Viruses · 2020Article
- Increasing the colon cancer cells sensitivity toward radiation therapy via application of Oct4-Sox2 complex decoy oligodeoxynucleotides.Molecular biology reports · 2020Article
- Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use.Biomolecules · 2019Article
- Intratumoral expression using a NFkB-based promoter enhances IL12 antitumor efficacy.Cancer gene therapy · 2019Article
- Vehicles of intercellular communication: exosomes and HIV-1.The Journal of general virology · 2019Review
- Tumor-derived nanovesicles promote lung distribution of the therapeutic nanovector through repression of Kupffer cell-mediated phagocytosis.Theranostics · 2019Article
- Improved Induction of Anti-Melanoma T Cells by Adenovirus-5/3 Fiber Modification to Target Human DCs.Vaccines · 2018Article
- Microgels produced using microfluidic on-chip polymer blending for controlled released of VEGF encoding lentivectors.Acta biomaterialia · 2018Article
- Dual MicroRNA to Cellular Prion Protein Inhibits Propagation of Pathogenic Prion Protein in Cultured Cells.Molecular neurobiology · 2018Article
- Article
- Article
- Engineering cell-based therapies to interface robustly with host physiology.Advanced drug delivery reviews · 2016Review
- Microfluidic models for adoptive cell-mediated cancer immunotherapies.Drug discovery today · 2016Review
- Novel delivery approaches for cancer therapeutics.Journal of controlled release : official journal of the Controlled Release Society · 2015Review
- In situ modulation of dendritic cells by injectable thermosensitive hydrogels for cancer vaccines in mice.Biomacromolecules · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lentiviral vectors have emerged as promising tools for both gene therapy and immunotherapy purposes. They exhibit several advantages over other viral systems in that they are less immunogenic and are capable of transducing a wide range of different cell types, including dendritic cells (DC). DC transduced ex vivo with a whole range of different (tumor) antigens were capable of inducing strong antigen-specific T-cell responses, both in vitro and in vivo. Recently, the administration of lentiviral vectors in vivo has gained substantial interest as an alternative method for antigen-specific immunization. This method offers a number of advantages over DC vaccines as the same lentivirus can in principle be used for all patients resulting in a significantly reduced cost and requirement for considerably less expertise for the generation and administration of lentiviral vaccines. By selectively targeting lentiviral vectors to, or restricting transgene expression in certain cell types, selectivity, safety and efficacy can be further improved. This review will focus on the use of direct administration of lentiviral vectors encoding tumor-associated antigens (TAA) for the induction of tumor-specific immune responses in vivo, with a special focus on problems related to the generation of large amounts of highly purified virus and specific targeting of antigen-presenting cells (APC).
Indexed as
Identifiers
17361214What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.